Compare Regeneron Pharmaceuticals Inc (REGN) vs Snowflake Inc (SNOW) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.

SNOW trades at $343.4, up 2.22% on the day, with a neutral technical signal and bullish moving averages. Revenue growth is strong, reaching $3.63B in 2025, but the company remains unprofitable with a net income margin of -20.07%. Recent news highlights a $3.75B convertible note offering and positive analyst coverage, with 81% of analysts rating it a Buy and a consensus price target of $418.03.

The outlook is mixed: robust revenue expansion and strategic partnerships offer upside, but persistent losses, high valuation multiples, and dilution risks from the note issuance pose significant challenges. Investor sentiment is cautiously optimistic, hinging on future profitability improvements.